Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption ...

The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign ...

Although financial incentives introduced by Japan's 2022 health policy did not result in a reduction in overall drug costs, ...

I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...

On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the ...

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...

Number 4: Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, ...

Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but ...

Early adopters of biosimilars have paved the way for broader acceptance by sharing real-world success strategies, overcoming initial resistance, and highlighting best practices for integration and ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, ...

Number 5: In 2 randomized controlled trials of maintenance therapy for inflammatory bowel disease (IBD), the subcutaneous formulation of the infliximab biosimilar CT-P13 demonstrated superiority to ...